A Phase 2 interventional study of VIR-2218 and pegylated interferon-alfa 2a in Chronic Hepatitis B, sponsored by Vir Biotechnology, Inc.. Completed at 22 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Vir Biotechnology, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Hepatitis B, Chronic with a site in Thailand — 3 open to participants now, 3 under way, none of them phase 3. Hepatitis B, Chronic · Thailand.
Among the 51 studies in Hepatitis B, Chronic with a site in Thailand, this one is the 30th largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2020, is one of 12 in phase 2, and was the 35th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 51 studies in Hepatitis B, Chronic with a site in Thailand are open now. Recruiting first, the newest first:
Institut de Recherche pour le Developpement · Sites in Thailand
Ages 15+ · Healthy volunteers
Siriraj Hospital · Sites in Thailand
Ages 18+
The Task Force for Global Health · Sites in Thailand
Healthy volunteers
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 17 · Phase 3 11 · Phase 4 5
First in 2002; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 126 across the 41 interventional studies, 1,655 across the 8 observational. Of the 43 that completed or were terminated, 22 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 51 have an industry lead sponsor. The 10 most frequent:
Vir Biotechnology, Inc. is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Vir Biotechnology, Inc. has 5 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 51 studies in Hepatitis B, Chronic with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VIR-2218 given by subcutaneous injection
Drug: VIR-2218
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a
VIR-2218 given by subcutaneous injection
Drug: VIR-2218
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
Drug: VIR-2218 · Drug: pegylated interferon-alfa 2a
VIR-2218 given by subcutaneous injection
Also known as: Elebsiran
pegylated interferon-alfa 2a given by subcutaneous injection
Also known as: pegylated interferon alpha-2a, PEG-IFNα
Number of Subjects With Adverse Events as Assessed by CTCAE v5.0
Time frame: Up to 148 Weeks
Number of Subjects With Abnormalities in Vital Signs, Electrocardiogram (ECG), and Clinically Significant Laboratory Findings
Time frame: Up to 148 Weeks
Mean Maximum Reduction of Serum HBsAg at Any Timepoint
Time frame: Up to 148 Weeks
Proportion of Subjects With Serum HBsAg Loss (Undetectable HBsAg) at Any Timepoint
Time frame: Up to 148 Weeks
Proportion of Subjects With Sustained Serum HBsAg Loss (Undetectable HBsAg) for Greater Than 6 Months
Time frame: Up to 148 Weeks
Proportion of Subjects With Anti-HBs Seroconversion at Any Timepoint
Anti-HBs seroconversion is defined as Anti-HBs quantitative value changed from baseline \<LLOQ (5 mIU/mL) to post-baseline\>=LLOQ.
Time frame: Up to 148 Weeks
For HBeAg-positive Patients: Proportion of Subjects With HBeAg Loss (Undetectable HBeAg) and/or Anti-HBe Seroconversion at Any Timepoint
Time frame: Up to 148 weeks
Phase 1 Part1 A-C data results are posted on clinicaltrials.gov in NCT03672188.
| Milestone | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|---|---|---|---|---|---|
| Started | 15 | 15 | 5 | 18 | 18 | 13 |
| Completed | 9 | 15 | 5 | 17 | 16 | 13 |
| Not completed | 6 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Rolled over to another study | 6 | 0 | 0 | 0 | 0 | 0 |
| Participants | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|---|---|---|---|---|---|
| Number of Subjects With Adverse Events as Assessed by CTCAE v5.0 | 9 | 13 | 3 | 16 | 17 | 13 |
| Participants | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|---|---|---|---|---|---|
| ALT Grade 1 | 2 | 12 | 2 | 12 | 14 | 9 |
| ALT Grade 2 | 0 | 1 | 1 | 2 | 2 | 2 |
| ALT Grade 3 | 0 | 0 | 0 | 1 | 1 | 0 |
| Alkaline phosphatase Grade 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| AST Grade 1 | 2 | 11 | 4 | 14 | 16 | 10 |
| AST Grade 2 | 0 | 2 | 0 | 2 | 0 | 0 |
| AST Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 |
| Bilirubin Grade 1 | 4 | 0 | 0 | 0 | 4 | 0 |
| Bilirubin Grade 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| Prothrombin, Internalized Normalized Ratio (INR) Grade 1 | 0 | 0 | 0 | 1 | 1 | 0 |
| Hemoglobin, anemia (g/DL) grade 1 | 0 | 2 | 0 | 2 | 5 | 8 |
| Hemoglobin, anemia (g/DL) grade 2 | 0 | 0 | 0 | 0 | 1 | 1 |
| Leukocytes, White blood cell decreased (10^9/L), grade 1 | 3 | 6 | 3 | 3 | 3 | 1 |
| Leukocytes, White blood cell decreased (10^9/L), grade 2 | 0 | 6 | 1 | 13 | 9 | 7 |
| Leukocytes, White blood cell decreased (10^9/L), grade 3 | 0 | 2 | 1 | 1 | 6 | 5 |
| Lymphocytes, Lymphocyte count decreased (10^9/L), grade 1 | 0 | 2 | 1 | 2 | 2 | 1 |
| Lymphocytes, Lymphocyte count decreased (10^9/L), grade 2 | 0 | 3 | 1 | 5 | 5 | 10 |
| Lymphocytes, Lymphocyte count decreased (10^9/L), grade 3 | 0 | 1 | 0 | 0 | 4 | 1 |
| Neutrophils, Neutrophil count decreased (10^9/L), grade 1 | 3 | 4 | 2 | 4 | 1 | 1 |
| Neutrophils, Neutrophil count decreased (10^9/L), grade 2 | 1 | 8 | 1 | 10 | 6 | 6 |
| Neutrophils, Neutrophil count decreased (10^9/L), grade 3 | 0 | 2 | 1 | 3 | 10 | 6 |
| Neutrophils, Neutrophil count decreased (10^9/L), grade 4 | 0 | 0 | 0 | 0 | 1 | 0 |
| Platelets, Platelet count decreased (10^9/L), grade 1 | 1 | 10 | 3 | 10 | 14 | 9 |
| Platelets, Platelet count decreased (10^9/L), grade 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Calcium, Hypocalcemia (mg/dL), grade 1 | 0 | 2 | 0 | 2 | 1 | 0 |
| Creatinine Clearance (mL/min), grade 1 | 6 | 4 | 2 | 7 | 6 | 2 |
| Creatinine Clearance (mL/min), grade 2 | 1 | 1 | 0 | 0 | 0 | 1 |
| Gamma Glutamyl Transferase (U/L), grade 1 | 1 | 8 | 2 | 8 | 6 | 5 |
| Gamma Glutamyl Transferase (U/L), grade 2 | 0 | 1 | 0 | 0 | 0 | 1 |
| Gamma Glutamyl Transferase (U/L), grade 3 | 0 | 0 | 0 | 0 | 1 | 0 |
| Glucose (mg/dL), grade 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| Lactate Dehydrogenase (U/L), grade 1 | 0 | 2 | 0 | 6 | 5 | 2 |
| Potassium, Hyperkalemia (mEq/L), grade 1 | 1 | 1 | 0 | 1 | 0 | 1 |
| Potassium, Hypokalemia (mEq/L), grade 2 | 0 | 0 | 0 | 0 | 1 | 1 |
| Sodium, Hypernatremia (mEq/L), grade 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Log 10 IU/mL | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|---|---|---|---|---|---|
| Mean Maximum Reduction of Serum HBsAg at Any Timepoint | -1.96 ± 0.29 | -2.15 ± 0.61 | -1.73 ± 0.37 | -2.52 ± 0.82 | -2.48 ± 1.41 | -2.99 ± 1.32 |
| Participants | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|---|---|---|---|---|---|
| Proportion of Subjects With Serum HBsAg Loss (Undetectable HBsAg) at Any Timepoint | 0 | 1 | 0 | 2 | 6 | 4 |
| Participants | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|---|---|---|---|---|---|
| Proportion of Subjects With Sustained Serum HBsAg Loss (Undetectable HBsAg) for Greater Than 6 Months | 0 | 1 | 0 | 1 | 4 | 2 |
Anti-HBs seroconversion is defined as Anti-HBs quantitative value changed from baseline \<LLOQ (5 mIU/mL) to post-baseline\>=LLOQ.
| Participants | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|---|---|---|---|---|---|
| Proportion of Subjects With Anti-HBs Seroconversion at Any Timepoint | 9 | 8 | 3 | 7 | 4 | 3 |
| Participants | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|---|---|---|---|---|---|
| HBeAg loss at any time | 1 | 1 | 0 | 3 | 3 | 1 |
| HBeAg loss with anti-HBe seroconversion at any time | 0 | 0 | 0 | 1 | 2 | 0 |
Collected over Treatment emergent serious adverse events were defined as AEs reported between Part 1D/2D: Day 1 through Week 27, Part 3D; Day 1 through Week 15, Part 1F: Day 1 through Week 27, Part 2F: Day 1 through Week 51, Part 3F: Day 1 through Week 52.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | 0/15 (0%) | 0/15 (0%) | 9/15 (60%) |
| Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | 0/15 (0%) | 0/15 (0%) | 13/15 (86.7%) |
| Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | 0/18 (0%) | 1/18 (5.6%) | 16/18 (88.9%) |
| Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | 0/18 (0%) | 1/18 (5.6%) | 17/18 (94.4%) |
| Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI | 0/13 (0%) | 1/13 (7.7%) | 13/13 (100%) |
| Event | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|---|---|---|---|---|---|
| Biliary colicHepatobiliary disorders | 0/15 | 0/15 | 0/5 | 0/18 | 0/18 | 1/13 |
| Ankle fractureInjury, poisoning and procedural complications | 0/15 | 0/15 | 0/5 | 1/18 | 0/18 | 0/13 |
| ManiaPsychiatric disorders | 0/15 | 0/15 | 0/5 | 0/18 | 1/18 | 0/13 |
| Event | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/15 | 0/15 | 0/5 | 0/18 | 2/18 | 6/13 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/15 | 1/15 | 1/5 | 6/18 | 3/18 | 4/13 |
| FatigueGeneral disorders | 0/15 | 5/15 | 1/5 | 2/18 | 2/18 | 1/13 |
| HeadacheNervous system disorders | 1/15 | 3/15 | 0/5 | 4/18 | 3/18 | 4/13 |
| Neutrophil count decreasedInvestigations | 0/15 | 1/15 | 1/5 | 1/18 | 4/18 | 4/13 |
| Influenza like illnessGeneral disorders | 0/15 | 2/15 | 0/5 | 2/18 | 2/18 | 4/13 |
| Injection site erythemaImmune system disorders | 1/15 | 2/15 | 1/5 | 2/18 | 5/18 | 2/13 |
| PyrexiaGeneral disorders | 0/15 | 3/15 | 0/5 | 3/18 | 5/18 | 2/13 |
| Back painMusculoskeletal and connective tissue disorders | 3/15 | 1/15 | 0/5 | 0/18 | 0/18 | 3/13 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/15 | 0/15 | 1/5 | 0/18 | 0/18 | 0/13 |
| Age, Categorical(Participants) | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 15 | 5 | 18 | 17 | 13 | 83 |
| >=65 years | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Age, Continuous(Years) | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI | Total |
|---|---|---|---|---|---|---|---|
| Mean | 50.3 ± 8.62 | 46.6 ± 7.80 | 46.2 ± 8.14 | 48.7 ± 5.79 | 45.2 ± 9.36 | 48.5 ± 7.55 | 47.7 ± 7.89 |
| Sex: Female, Male(Participants) | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 1 | 4 | 3 | 6 | 18 |
| Male | 13 | 13 | 4 | 14 | 15 | 7 | 66 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 15 | 15 | 5 | 18 | 18 | 13 | 84 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 12 | 13 | 5 | 16 | 18 | 13 | 77 |
| Native Hawaiian or Other Pacific Islander | 3 | 2 | 0 | 1 | 0 | 0 | 6 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI | Total |
|---|---|---|---|---|---|---|---|
| New Zealand | 6 | 3 | 1 | 2 | 3 | 0 | 15 |
| South Korea | 7 | 6 | 4 | 10 | 4 | 9 | 40 |
| Hong Kong | 1 | 1 | 0 | 0 | 5 | 3 | 10 |
| Malaysia | 0 | 2 | 0 | 3 | 0 | 0 | 5 |
| Australia | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Thailand | 1 | 2 | 0 | 3 | 6 | 1 | 13 |
| Hepatitis B surface antigen (Log10 IU/mL)(Log10 IU/mL) | Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI | Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI | Cohort 3d: VIR-2218 200 mg Q4W x 3 + PEG-IFNα 180 µg QW x 12 on NRTI | Cohort 1f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 24 on NRTI | Cohort 2f: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x ≤ 48 on NRTI | Cohort 3f: VIR-2218 200 mg Q4W x ≤13 + PEG-IFNα 180 µg QW x ≤ 44 on NRTI | Total |
|---|---|---|---|---|---|---|---|
| Mean | 3.44 ± 0.447 | 3.20 ± 0.676 | 3.39 ± 1.039 | 3.28 ± 0.726 | 2.90 ± 0.818 | 3.35 ± 0.696 | 3.23 ± 0.717 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Mar 2024, 44 months.
Results were first posted in Apr 2026, 2 years after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 44 months is above that.
Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elebsiran